October 1, 2024

Supplementary Figure S7 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Key Points

Key points are not available for this paper at this time.

Abstract

Supplementary Figure S7 shows the improved antiproliferative activity observed with the MRTX0902/avutometinib combination in KRAS-MAPK pathway mutant models, LN229 (PTPN11 A72S) and NCI-H1435 (NF1 K615N).

Bookmark

Supplementary Figure S7 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Key Points

Abstract

Cite This Study

Also Consider

Also Consider